{"gene":"CXCL9","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1995,"finding":"Recombinant human CXCL9 (Mig) induces transient elevation of intracellular Ca2+ and is chemotactic for tumor-infiltrating T lymphocytes and activated peripheral blood lymphocytes, but not neutrophils, monocytes, or B cells. Proteolytic cleavage at basic carboxy-terminal residues generates multiple secreted species of lower specific activity compared to full-length CXCL9.","method":"Calcium flux assay, modified Boyden chamber chemotaxis assay, SDS-PAGE of CHO-expressed recombinant protein, carboxy-terminal truncation analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — multiple in vitro functional assays with recombinant protein and structure-activity analysis in single study","pmids":["7595201"],"is_preprint":false},{"year":1997,"finding":"CXCL9 (Mig) and CXCL10 (IP-10) share the receptor CXCR3 on activated T cells, show reciprocal desensitization, and both inhibit neovascularization and hematopoietic progenitor cells while exerting antitumor effects.","method":"Reciprocal desensitization assays on activated T cells, in vitro and in vivo functional assays","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — receptor sharing confirmed by reciprocal desensitization, replicated across multiple assays","pmids":["9060447"],"is_preprint":false},{"year":2004,"finding":"CXCL9 and CXCL10 predominantly require the CXCR3 carboxyl-terminal domain and beta-arrestin1 for receptor internalization, whereas CXCL11 predominantly requires the third intracellular loop. Chemotaxis and calcium mobilization by all three ligands depend on the CXCR3 carboxyl terminus and the DRY sequence in the third transmembrane domain.","method":"CXCR3 domain deletion/mutation constructs, internalization assays, chemotaxis assays, calcium mobilization assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of receptor intracellular domains with multiple functional readouts","pmids":["15150261"],"is_preprint":false},{"year":1998,"finding":"CXCL9 (Mig) contributes to the antitumor effects of IL-12 by inhibiting tumor vasculature; neutralizing antibodies to CXCL9 and CXCL10 substantially reduced the antitumor efficacy of local IL-12 treatment in athymic mice.","method":"In vivo neutralizing antibody treatment, tumor volume and survival measurement, gene/protein expression in tumor tissue","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo antibody neutralization with functional antitumor readout, single study","pmids":["9738666"],"is_preprint":false},{"year":2002,"finding":"CXCL9 is required for CD4+ T lymphocyte recruitment and development of cardiac allograft vasculopathy; antibody neutralization of CXCL9 significantly reduced CD4+ T cell infiltration and intimal thickening. Macrophages (MOMA-2+) are the predominant source of CXCL9, and recipient CD4+ T cells are required for sustained CXCL9 production.","method":"In vivo antibody neutralization, histological assessment of intimal thickening, immunohistochemistry for CXCL9 source identification, MHC II-mismatched murine CAV model","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — in vivo neutralization with specific cellular phenotype readout, cell source identified by immunohistochemistry","pmids":["12368204"],"is_preprint":false},{"year":2005,"finding":"CXCL9 inhibits eosinophil chemoattraction and function via CCR3 and a Rac2-dependent mechanism: CXCL9 pretreatment blocks eotaxin-induced Rac GTPase activation and F-actin assembly, and this inhibitory activity is absent in CCR3-deficient and Rac2-deficient eosinophils.","method":"F-actin formation assay, chemotaxis assay, Rac GTPase activation assay, CCR3 and Rac2 gene-targeted cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — receptor and signaling molecule identified by genetic knockout plus functional assays","pmids":["15802529"],"is_preprint":false},{"year":2007,"finding":"CXCL9 (MIG) exerts direct antibacterial activity against Streptococcus pyogenes; inhibition of CXCL9 expression reduces antibacterial activity at the surface of inflamed pharyngeal cells. S. pyogenes M1 secretes SIC (streptococcal inhibitor of complement) which inhibits the antibacterial activity of CXCL9.","method":"In vitro antibacterial assay, siRNA inhibition of CXCL9 expression in pharyngeal cells, tonsil fluid protein measurement","journal":"The Journal of infectious diseases","confidence":"Medium","confidence_rationale":"Tier 2 — direct antibacterial function demonstrated with knockdown and inhibitor, single study","pmids":["17262710"],"is_preprint":false},{"year":2016,"finding":"Osteoblast-derived CXCL9 acts as an angiostatic factor by interacting with VEGF and preventing its binding to endothelial cells and osteoblasts, thereby inhibiting angiogenesis and osteogenesis. mTORC1 activates CXCL9 expression in osteoblasts by upregulating STAT1 transcription and increasing STAT1 binding to the CXCL9 promoter.","method":"In vitro binding assays (CXCL9-VEGF interaction), in vivo mouse bone models, ChIP assay (STAT1 binding to CXCL9 promoter), mTORC1 inhibition experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — direct protein-protein interaction, promoter ChIP, in vivo rescue experiments with multiple orthogonal methods","pmids":["27966526"],"is_preprint":false},{"year":2019,"finding":"Macrophages are the predominant source of CXCL9 in tumors following dual PD-1/CTLA-4 immune checkpoint blockade; macrophage depletion abrogated CXCL9 production, CD8+ T cell infiltration, and therapeutic efficacy of ICB. CXCL9-mediated T cell recruitment is CXCR3-dependent.","method":"Macrophage depletion, neutralizing antibodies, NanoString analysis, flow cytometry, cytometric bead array, single-cell RNA-seq in patients","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — macrophage depletion plus CXCR3 blockade with functional T cell recruitment readout, confirmed in murine models and patient scRNA-seq","pmids":["31636098"],"is_preprint":false},{"year":2021,"finding":"CXCL9, CXCL10, and CXCL11 gene expression is induced in SARS-CoV-2-infected Calu-3 lung epithelial cells via AKT-dependent signaling; treatment with the AKT inhibitor GSK690693 markedly reduced induction of these chemokines.","method":"Small molecule kinase inhibitor treatment (GSK690693), RT-qPCR, transgenic ACE2 mouse model infection","journal":"Viruses","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibition identifies AKT pathway, confirmed in vivo, single study","pmids":["34205098"],"is_preprint":false},{"year":2018,"finding":"CXCL9/10/11 signaling through CXCR3 upregulates PD-L1 expression in gastric cancer cells by activating the STAT3 and PI3K-Akt signaling pathways; blocking CXCR3 signaling diminished both PD-L1 upregulation and STAT3/Akt activation.","method":"Western blot for pSTAT3 and pAkt, CXCL9/10/11 stimulation and CXCR3 blockade, in vitro and in vivo experiments","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway activation confirmed by western blot with receptor blockade rescue, single study","pmids":["29690901"],"is_preprint":false},{"year":2014,"finding":"CXCL9 promotes invasion of hepatocellular carcinoma cells by upregulating PREX2 (a Rac GTPase guanine nucleotide exchange factor) downstream of CXCR3/GPCR signaling; siRNA knockdown of PREX2 reduced CXCL9-enhanced invasion.","method":"Transwell invasion assay, recombinant CXCL9 treatment, PREX2 siRNA knockdown, RT-PCR","journal":"Journal of molecular histology","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional invasion assay with siRNA knockdown identifying PREX2 as downstream effector, single study","pmids":["25151370"],"is_preprint":false},{"year":2014,"finding":"CXCL9 inhibits proliferation of epithelial cells via activation of phospho-p70S6K, which promotes TGF-β secretion as a downstream mediator; p70S6K inhibition abolished this effect. CXCL9/CXCR3 interaction exacerbates chemotherapy-induced intestinal damage.","method":"Cell proliferation assay (MCF10A), ELISA for TGF-β, p70S6K inhibitor treatment, in vivo 5-FU mucositis mouse model, anti-CXCL9 antibody treatment","journal":"Journal of cancer research and clinical oncology","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway (p70S6K→TGF-β) identified with inhibitor and in vivo antibody rescue, single study","pmids":["25398650"],"is_preprint":false},{"year":2022,"finding":"CXCL9, but not CXCL10, inhibits collagen deposition in human pulmonary arterial smooth muscle cells via CXCR3, acting downstream of NKT cell-activated STAT1 signaling. This NKT-STAT1-CXCL9-CXCR3 axis opposes vascular fibrosis in pulmonary hypertension.","method":"CXCL9/CXCL10 treatment of hPASMCs, collagen deposition assay, CXCR3 blocking, NKT cell coculture, in vivo NKT cell activation (KRN7000), secretome analysis","journal":"American journal of respiratory and critical care medicine","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific (CXCR3) antifibrotic effect confirmed in vitro and in vivo, pathway defined by multiple orthogonal approaches","pmids":["35763380"],"is_preprint":false},{"year":2023,"finding":"CXCL9 drives skin fibrosis through CXCR3-dependent upregulation of Col1a1 in fibroblasts; Cxcl9-deficient and Cxcr3-deficient mice were protected from bleomycin-induced dermal fibrosis. Recombinant CXCL9, but not CXCL10, directly induced Col1a1 mRNA in cultured mouse fibroblasts.","method":"Cxcl9-/-, Cxcl10-/-, Cxcr3-/- knockout mouse bleomycin fibrosis model, recombinant CXCL9/CXCL10 treatment of fibroblasts, REX3 reporter mice for cell source tracking, RT-PCR for Col1a1","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 1-2 — genetic knockout of chemokine and receptor plus direct recombinant protein stimulation with gene expression readout","pmids":["36708947"],"is_preprint":false},{"year":2022,"finding":"CXCL9 overexpression in murine ovarian cancer models results in T cell accumulation and improved survival in an adaptive immune-dependent manner, and is sufficient to enable successful anti-PD-L1 therapy in otherwise ICB-resistant tumors.","method":"CXCL9 overexpression in ID8-Trp53-/- and ID8-Trp53-/-Brca2-/- mouse models, T cell depletion, anti-PD-L1 treatment, survival analysis","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo overexpression with adaptive immunity dependence confirmed by T cell depletion, single study","pmids":["35314795"],"is_preprint":false},{"year":2019,"finding":"CXCL9 stimulates proliferation and migration of cardiac fibroblasts; serum CXCL9 is elevated after myocardial infarction and in isoproterenol-treated rats with cardiac fibrosis.","method":"In vitro cardiac fibroblast proliferation and migration assays with CXCL9 treatment, ELISA in patient sera and rat model","journal":"Journal of clinical medicine","confidence":"Low","confidence_rationale":"Tier 3 — single in vitro functional assay, no mechanistic pathway identified","pmids":["31083544"],"is_preprint":false},{"year":2023,"finding":"Glucocorticoids act directly on renal tubular epithelial cells (not on T cells) to abolish CXCL9 and CXCL10 expression, thereby preventing CXCR3+CD4+ T cell recruitment to inflamed kidneys and protecting from immune-mediated glomerulonephritis.","method":"In vivo crescentic glomerulonephritis model with steroid treatment, in vitro steroid treatment of tubular epithelial cells and T cells, single-cell and morphological analyses of kidney biopsies","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — cell-specific mechanism confirmed by in vitro dissection plus in vivo model, single study","pmids":["36355429"],"is_preprint":false},{"year":2025,"finding":"DPP-4 cleaves the two N-terminal amino acids of CXCL9, converting it from a CXCR3 agonist to a competitive antagonist that can still bind CXCR3 but no longer activates it. Addition of an N-terminal glutamine renders CXCL9-Fc resistant to DPP-4 cleavage while retaining full CXCR3 agonist activity.","method":"Biochemical DPP-4 cleavage assays, computational modeling, CXCR3 activation assays, N-terminal glutamine mutant engineering","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — biochemical assay with structure-activity mutagenesis defining DPP-4 as a post-translational modifier that converts CXCL9 into a CXCR3 antagonist","pmids":["40238455"],"is_preprint":false},{"year":2019,"finding":"CXCL9-expressing proinflammatory macrophages (F480+MHCII+Ly6Clo) are the primary source of CXCL9 in tumors; the efficacy of anti-PD-L1 (avelumab) is dependent on both Cxcr3 and Cxcl9, as demonstrated in mouse tumor models.","method":"scRNA-seq, flow cytometry, Cxcr3 and Cxcl9 functional dependence in murine tumor models, pre-treatment biopsy analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — CXCL9/CXCR3 functional requirement confirmed in vivo, macrophage source confirmed by scRNA-seq and flow cytometry","pmids":["32640238"],"is_preprint":false},{"year":1999,"finding":"CXCL9 (Mig) directly induces proliferation of human mesangial cells in vitro through functional CXCR3 expressed on these cells, in addition to its role as a chemoattractant.","method":"Flow cytometry for CXCR3 on mesangial cells, intracellular Ca2+ influx assay, mesangial cell proliferation assay with CXCL9/IP-10 treatment","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 — receptor expression confirmed plus direct functional proliferation assay, single study","pmids":["10589690"],"is_preprint":false},{"year":2019,"finding":"In murine CXCL9/10-engineered dendritic cell vaccination, antitumor efficacy is dependent on CD4+ and CD8+ T cells and CXCR3-dependent T cell trafficking from the lymph node, establishing the mechanistic requirement for the CXCL9-CXCR3 axis in DC-mediated immune activation.","method":"CD4/CD8 T cell depletion, CXCR3 blockade, intratumoral dendritic cell vaccination in murine NSCLC models, flow cytometry","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 — CXCR3-dependent trafficking mechanistically confirmed by blockade in vivo, single study","pmids":["38518770"],"is_preprint":false},{"year":2024,"finding":"In cervical cancer, HPV proteins E6 and E7 induce LIF expression via the NFκB pathway, and LIF represses CXCL9 expression in tumor-associated macrophages; LIF blockade restores CXCL9 production and promotes CD8+ T cell tumor infiltration.","method":"Primary pDC and macrophage cultures, LIF blockade, syngeneic animal models, patient-derived tumor models, IFN-γ pathway analysis","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — upstream repressor (LIF via NFκB) and downstream consequence (CXCL9, CD8+ T infiltration) defined by intervention studies, single study","pmids":["39078728"],"is_preprint":false},{"year":2019,"finding":"CXCL9 secreted by osteoblast-derived MSCs in osteogenic conditions acts via mTOR/STAT1 signaling to counter-regulate VEGF and suppress angiogenesis in MSC-endothelial co-culture; rapamycin inhibition of mTOR reduced CXCL9 and restored angiogenic capacity.","method":"MSC-HUVEC co-culture, rapamycin treatment, VEGF binding competition assay, osteogenic differentiation assay","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 — mTOR/STAT1 pathway confirmed by pharmacological inhibition with functional angiogenesis readout, single study","pmids":["31550444"],"is_preprint":false}],"current_model":"CXCL9 (MIG) is an IFN-γ-inducible CXC chemokine that signals primarily through CXCR3 on activated T and NK cells to drive chemotaxis and calcium flux; it is subject to DPP-4-mediated N-terminal cleavage that converts it into a CXCR3 competitive antagonist, and it exerts angiostatic effects by directly binding and sequestering VEGF. It inhibits eosinophil responses via CCR3/Rac2-dependent disruption of actin cytoskeletal signaling, can drive fibroblast collagen synthesis (Col1a1) and skin fibrosis via CXCR3, and is produced predominantly by macrophages (under mTORC1/STAT1 control) to recruit CXCR3+ cytotoxic T cells in tumor and inflammatory contexts."},"narrative":{"teleology":[{"year":1995,"claim":"Establishing that CXCL9 is a T-cell-selective chemoattractant resolved the cellular target specificity of this IFN-γ-inducible chemokine and showed that its C-terminal basic tail modulates bioactivity.","evidence":"Recombinant CXCL9 calcium flux and Boyden chamber chemotaxis on TILs and PBLs; C-terminal truncation analysis","pmids":["7595201"],"confidence":"High","gaps":["Receptor identity unknown at this stage","In vivo relevance of C-terminal processing not tested","Mechanism of T-cell selectivity undefined"]},{"year":1997,"claim":"Identifying CXCR3 as the shared receptor for CXCL9, CXCL10, and CXCL11 unified these IFN-γ-inducible chemokines into a single signaling axis and linked them to antiangiogenic and antitumor activity.","evidence":"Reciprocal desensitization assays on activated T cells; neovascularization and hematopoietic progenitor inhibition assays","pmids":["9060447"],"confidence":"High","gaps":["Ligand-specific signaling bias through CXCR3 not resolved","Structural basis of receptor recognition unknown"]},{"year":1998,"claim":"Demonstrating that neutralizing CXCL9 reduced IL-12-mediated tumor regression in vivo established its non-redundant role as an angiostatic effector in antitumor immunity.","evidence":"In vivo anti-CXCL9 neutralizing antibody in athymic mouse tumor models","pmids":["9738666"],"confidence":"Medium","gaps":["Cannot distinguish T-cell-independent angiostatic from immune-mediated antitumor effects in this system","Contribution of CXCL10 not fully separated"]},{"year":2002,"claim":"Showing that macrophages are the predominant CXCL9 source and that CXCL9 neutralization blocks CD4⁺ T cell recruitment defined the macrophage–CXCL9–T cell axis in transplant vasculopathy.","evidence":"Anti-CXCL9 antibody in MHC II-mismatched murine cardiac allograft model; MOMA-2 immunohistochemistry for cell source","pmids":["12368204"],"confidence":"High","gaps":["Relative contribution of CXCL10/11 not fully controlled","Downstream intracellular signaling in recruited T cells not addressed"]},{"year":2004,"claim":"Mapping the CXCR3 domains required for CXCL9-driven internalization, chemotaxis, and calcium mobilization revealed that CXCL9 signals preferentially through the receptor's C-terminal tail and β-arrestin1, distinct from CXCL11.","evidence":"CXCR3 deletion/point mutant constructs with internalization, chemotaxis, and calcium flux readouts","pmids":["15150261"],"confidence":"High","gaps":["Biased signaling consequences (G-protein vs. β-arrestin) not measured for downstream gene expression","No structural data for ligand–receptor interface"]},{"year":2005,"claim":"Discovering that CXCL9 inhibits eosinophil responses through CCR3 and Rac2 revealed a CXCR3-independent anti-inflammatory mechanism acting on allergic effector cells.","evidence":"CCR3⁻/⁻ and Rac2⁻/⁻ eosinophils; F-actin, Rac-GTP, and chemotaxis assays","pmids":["15802529"],"confidence":"High","gaps":["Binding mode of CXCL9 to CCR3 not structurally defined","In vivo relevance in allergic disease not tested"]},{"year":2007,"claim":"Finding that CXCL9 has direct antimicrobial activity against Streptococcus pyogenes expanded its function beyond chemotaxis to innate host defense, while identifying SIC as a bacterial counter-strategy.","evidence":"In vitro bactericidal assay; siRNA knockdown in pharyngeal epithelial cells","pmids":["17262710"],"confidence":"Medium","gaps":["Antimicrobial mechanism (membrane disruption vs. other) not defined","In vivo contribution to pharyngeal defense not quantified"]},{"year":2016,"claim":"Demonstrating that CXCL9 directly binds VEGF to block its receptor engagement, and that mTORC1/STAT1 drives CXCL9 transcription, defined a transcriptional–angiostatic circuit operating in osteoblasts.","evidence":"CXCL9–VEGF binding assay, STAT1 ChIP on CXCL9 promoter, mTORC1 inhibition, in vivo bone models","pmids":["27966526"],"confidence":"High","gaps":["Stoichiometry and affinity of CXCL9–VEGF interaction not quantified biophysically","Relative contribution of CXCR3-mediated vs. VEGF-sequestration-mediated angiostasis not separated in vivo"]},{"year":2019,"claim":"Multiple groups converged on tumor-associated macrophages as the critical CXCL9 source required for CXCR3-dependent CD8⁺ T cell infiltration and anti-PD-1/PD-L1 efficacy, establishing CXCL9 as a gatekeeper of checkpoint immunotherapy response.","evidence":"Macrophage depletion, CXCR3/CXCL9 genetic or antibody blockade in murine tumor models; patient scRNA-seq validation","pmids":["31636098","32640238"],"confidence":"High","gaps":["Signals that sustain macrophage CXCL9 production in the tumor microenvironment beyond IFN-γ not fully mapped","Whether CXCL9 vs. CXCL10 have non-redundant roles in human ICB response not resolved"]},{"year":2022,"claim":"Identifying opposing fibrotic roles — CXCL9 inhibits collagen deposition in pulmonary vascular smooth muscle yet promotes dermal fibrosis via fibroblast Col1a1 induction — revealed that CXCR3-mediated fibrotic outcomes are tissue- and cell-type-specific.","evidence":"hPASMC collagen assay with CXCR3 blockade (pulmonary); Cxcl9⁻/⁻ and Cxcr3⁻/⁻ mice in bleomycin skin fibrosis model with direct fibroblast stimulation (dermal)","pmids":["35763380","36708947"],"confidence":"High","gaps":["Downstream transcription factors linking CXCR3 to Col1a1 induction in fibroblasts not identified","Whether DPP-4 cleavage modulates fibrotic vs. antifibrotic activity not tested"]},{"year":2025,"claim":"Defining DPP-4 as a post-translational switch that converts full-length CXCL9 from a CXCR3 agonist to a competitive antagonist explained how proteolytic processing negatively regulates the CXCL9–CXCR3 axis and opened a strategy for engineering cleavage-resistant variants.","evidence":"Biochemical DPP-4 cleavage assay, CXCR3 activation assay, N-terminal glutamine mutant engineering","pmids":["40238455"],"confidence":"High","gaps":["In vivo impact of DPP-4-processed CXCL9 on T cell recruitment and tumor immunity not demonstrated","Whether DPP-4-cleaved CXCL9 retains VEGF-binding or antimicrobial activities unknown"]},{"year":null,"claim":"Key unresolved questions include the structural basis of CXCL9–CXCR3 vs. CXCL9–CCR3 binding selectivity, the intracellular signaling cascade linking CXCR3 to opposing fibrotic outcomes in different cell types, and whether DPP-4-mediated antagonist conversion operates in vivo to shape tumor immune evasion.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal/cryo-EM structure of CXCL9 bound to CXCR3 or CCR3","Signaling divergence downstream of CXCR3 in fibroblasts vs. smooth muscle cells undefined","In vivo functional relevance of DPP-4-cleaved CXCL9 antagonism not tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,18]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[7,23]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,4,7,8]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,8,19,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,10,11]}],"complexes":[],"partners":["CXCR3","CCR3","VEGF","DPP4","STAT1","PREX2"],"other_free_text":[]},"mechanistic_narrative":"CXCL9 (MIG) is an interferon-γ-inducible CXC chemokine that orchestrates immune cell trafficking, angiostasis, and tissue remodeling through CXCR3-dependent and CXCR3-independent mechanisms. It signals through CXCR3 on activated T cells and NK cells to elicit calcium flux and chemotaxis — requiring the receptor's carboxyl-terminal domain, DRY motif, and β-arrestin1 for internalization — and is the principal macrophage-derived chemokine that recruits CXCR3⁺ CD8⁺ T cells into tumors, a function essential for the efficacy of immune checkpoint blockade [PMID:7595201, PMID:15150261, PMID:32640238, PMID:31636098]. DPP-4 cleaves the two N-terminal residues of CXCL9 converting it from a CXCR3 agonist into a competitive antagonist, while CXCL9 also exerts angiostatic activity by directly binding and sequestering VEGF downstream of mTORC1/STAT1-driven transcription [PMID:40238455, PMID:27966526]. Beyond immune recruitment, CXCL9 inhibits eosinophil function through CCR3/Rac2-dependent disruption of actin polymerization, directly induces Col1a1 in fibroblasts to promote dermal fibrosis via CXCR3, and opposes vascular smooth-muscle collagen deposition in pulmonary hypertension, illustrating context-dependent pro- and anti-fibrotic roles [PMID:15802529, PMID:36708947, PMID:35763380]."},"prefetch_data":{"uniprot":{"accession":"Q07325","full_name":"C-X-C motif chemokine 9","aliases":["Gamma-interferon-induced monokine","Monokine induced by interferon-gamma","HuMIG","MIG","Small-inducible cytokine B9"],"length_aa":125,"mass_kda":14.0,"function":"Cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. Chemotactic for activated T-cells. Binds to CXCR3","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q07325/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCL9","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCL9","total_profiled":1310},"omim":[{"mim_id":"620430","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 3; ADMIO3","url":"https://www.omim.org/entry/620430"},{"mim_id":"615439","title":"MACULAR DEGENERATION, AGE-RELATED, 13; ARMD13","url":"https://www.omim.org/entry/615439"},{"mim_id":"612923","title":"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3; AHUS3","url":"https://www.omim.org/entry/612923"},{"mim_id":"610984","title":"COMPLEMENT FACTOR I DEFICIENCY; CFID","url":"https://www.omim.org/entry/610984"},{"mim_id":"604378","title":"BECLIN 1; BECN1","url":"https://www.omim.org/entry/604378"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":290.0}],"url":"https://www.proteinatlas.org/search/CXCL9"},"hgnc":{"alias_symbol":["SCYB9","Humig","crg-10"],"prev_symbol":["CMK","MIG"]},"alphafold":{"accession":"Q07325","domains":[{"cath_id":"2.40.50.40","chopping":"32-121","consensus_level":"high","plddt":91.3576,"start":32,"end":121}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07325","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07325-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07325-F1-predicted_aligned_error_v6.png","plddt_mean":87.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCL9","jax_strain_url":"https://www.jax.org/strain/search?query=CXCL9"},"sequence":{"accession":"Q07325","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07325.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07325/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07325"}},"corpus_meta":[{"pmid":"29207310","id":"PMC_29207310","title":"CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.","date":"2017","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29207310","citation_count":1157,"is_preprint":false},{"pmid":"9060447","id":"PMC_9060447","title":"Mig and IP-10: CXC chemokines that target lymphocytes.","date":"1997","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9060447","citation_count":655,"is_preprint":false},{"pmid":"31636098","id":"PMC_31636098","title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31636098","citation_count":555,"is_preprint":false},{"pmid":"37535729","id":"PMC_37535729","title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37535729","citation_count":452,"is_preprint":false},{"pmid":"7595201","id":"PMC_7595201","title":"Human Mig chemokine: biochemical and functional characterization.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7595201","citation_count":314,"is_preprint":false},{"pmid":"11523046","id":"PMC_11523046","title":"Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation.","date":"2001","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11523046","citation_count":289,"is_preprint":false},{"pmid":"18458155","id":"PMC_18458155","title":"Kindlin-2 (Mig-2): a co-activator of beta3 integrins.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18458155","citation_count":283,"is_preprint":false},{"pmid":"27490802","id":"PMC_27490802","title":"CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.","date":"2016","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27490802","citation_count":218,"is_preprint":false},{"pmid":"15150261","id":"PMC_15150261","title":"Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15150261","citation_count":215,"is_preprint":false},{"pmid":"29893515","id":"PMC_29893515","title":"CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.","date":"2018","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/29893515","citation_count":161,"is_preprint":false},{"pmid":"9738666","id":"PMC_9738666","title":"Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12.","date":"1998","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9738666","citation_count":131,"is_preprint":false},{"pmid":"27966526","id":"PMC_27966526","title":"Osteoblasts secrete Cxcl9 to regulate angiogenesis in bone.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27966526","citation_count":121,"is_preprint":false},{"pmid":"16819504","id":"PMC_16819504","title":"Evidence that MIG-6 is a tumor-suppressor gene.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16819504","citation_count":109,"is_preprint":false},{"pmid":"2665839","id":"PMC_2665839","title":"Growth and differentiation of a human megakaryoblastic cell line, CMK.","date":"1989","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2665839","citation_count":105,"is_preprint":false},{"pmid":"34205098","id":"PMC_34205098","title":"The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner.","date":"2021","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/34205098","citation_count":105,"is_preprint":false},{"pmid":"10589690","id":"PMC_10589690","title":"Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis.","date":"1999","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/10589690","citation_count":102,"is_preprint":false},{"pmid":"20351267","id":"PMC_20351267","title":"Mig-6 controls EGFR trafficking and suppresses gliomagenesis.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20351267","citation_count":99,"is_preprint":false},{"pmid":"11091274","id":"PMC_11091274","title":"CXC chemokines Gro(alpha)/IL-8 and IP-10/MIG in Helicobacter pylori gastritis.","date":"2000","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11091274","citation_count":85,"is_preprint":false},{"pmid":"19439667","id":"PMC_19439667","title":"Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19439667","citation_count":80,"is_preprint":false},{"pmid":"17262710","id":"PMC_17262710","title":"The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17262710","citation_count":79,"is_preprint":false},{"pmid":"38518770","id":"PMC_38518770","title":"CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38518770","citation_count":78,"is_preprint":false},{"pmid":"29690901","id":"PMC_29690901","title":"CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29690901","citation_count":78,"is_preprint":false},{"pmid":"17351343","id":"PMC_17351343","title":"Mig-6, signal transduction, stress response and cancer.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17351343","citation_count":76,"is_preprint":false},{"pmid":"12387890","id":"PMC_12387890","title":"Mitogen-inducible gene 6 (MIG-6), adipophilin and tuftelin are inducible by hypoxia.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12387890","citation_count":76,"is_preprint":false},{"pmid":"23352833","id":"PMC_23352833","title":"Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy.","date":"2013","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/23352833","citation_count":73,"is_preprint":false},{"pmid":"11429782","id":"PMC_11429782","title":"Induction of the SAPK activator MIG-6 by the alkylating agent methyl methanesulfonate.","date":"2001","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11429782","citation_count":68,"is_preprint":false},{"pmid":"27576738","id":"PMC_27576738","title":"Interleukin-6, MCP-1, IP-10, and MIG are sequentially expressed in cerebrospinal fluid after subarachnoid hemorrhage.","date":"2016","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27576738","citation_count":66,"is_preprint":false},{"pmid":"18499456","id":"PMC_18499456","title":"CED-10/Rac1 mediates axon guidance by regulating the asymmetric distribution of MIG-10/lamellipodin.","date":"2008","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/18499456","citation_count":66,"is_preprint":false},{"pmid":"32640238","id":"PMC_32640238","title":"Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32640238","citation_count":61,"is_preprint":false},{"pmid":"7641805","id":"PMC_7641805","title":"Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation.","date":"1995","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/7641805","citation_count":60,"is_preprint":false},{"pmid":"35314795","id":"PMC_35314795","title":"CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35314795","citation_count":59,"is_preprint":false},{"pmid":"37395276","id":"PMC_37395276","title":"Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/37395276","citation_count":58,"is_preprint":false},{"pmid":"16672984","id":"PMC_16672984","title":"Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.","date":"2006","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16672984","citation_count":57,"is_preprint":false},{"pmid":"30410928","id":"PMC_30410928","title":"AC-YVAD-CMK Inhibits Pyroptosis and Improves Functional Outcome after Intracerebral Hemorrhage.","date":"2018","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/30410928","citation_count":55,"is_preprint":false},{"pmid":"20418913","id":"PMC_20418913","title":"The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20418913","citation_count":54,"is_preprint":false},{"pmid":"12368204","id":"PMC_12368204","title":"The role of MIG/CXCL9 in cardiac allograft vasculopathy.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12368204","citation_count":52,"is_preprint":false},{"pmid":"28253295","id":"PMC_28253295","title":"Tissue-specific regulation of CXCL9/10/11 chemokines in keratinocytes: Implications for oral inflammatory disease.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28253295","citation_count":51,"is_preprint":false},{"pmid":"12473267","id":"PMC_12473267","title":"IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver.","date":"2002","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12473267","citation_count":49,"is_preprint":false},{"pmid":"35763380","id":"PMC_35763380","title":"Impairment of the NKT-STAT1-CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis.","date":"2022","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35763380","citation_count":48,"is_preprint":false},{"pmid":"22701735","id":"PMC_22701735","title":"Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22701735","citation_count":45,"is_preprint":false},{"pmid":"28450066","id":"PMC_28450066","title":"Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28450066","citation_count":45,"is_preprint":false},{"pmid":"31836011","id":"PMC_31836011","title":"The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31836011","citation_count":44,"is_preprint":false},{"pmid":"37937817","id":"PMC_37937817","title":"The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment.","date":"2024","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37937817","citation_count":43,"is_preprint":false},{"pmid":"25377472","id":"PMC_25377472","title":"Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25377472","citation_count":40,"is_preprint":false},{"pmid":"32060845","id":"PMC_32060845","title":"The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060845","citation_count":39,"is_preprint":false},{"pmid":"35352167","id":"PMC_35352167","title":"CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/35352167","citation_count":38,"is_preprint":false},{"pmid":"19029086","id":"PMC_19029086","title":"Regulation of CXCL9/10/11 in oral keratinocytes and fibroblasts.","date":"2008","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/19029086","citation_count":38,"is_preprint":false},{"pmid":"31699671","id":"PMC_31699671","title":"The Role of CXCL13 and CXCL9 in Early Breast Cancer.","date":"2019","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31699671","citation_count":37,"is_preprint":false},{"pmid":"1998594","id":"PMC_1998594","title":"Interleukin 6, a possible autocrine growth and differentiation factor for the human megakaryocytic cell line, CMK.","date":"1991","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/1998594","citation_count":37,"is_preprint":false},{"pmid":"19340290","id":"PMC_19340290","title":"ESAT6-induced IFNgamma and CXCL9 can differentiate severity of tuberculosis.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19340290","citation_count":36,"is_preprint":false},{"pmid":"23028145","id":"PMC_23028145","title":"Synaptic vesicle clustering requires a distinct MIG-10/Lamellipodin isoform and ABI-1 downstream from Netrin.","date":"2012","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/23028145","citation_count":36,"is_preprint":false},{"pmid":"31083544","id":"PMC_31083544","title":"Potential Effects of CXCL9 and CCL20 on Cardiac Fibrosis in Patients with Myocardial Infarction and Isoproterenol-Treated Rats.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31083544","citation_count":36,"is_preprint":false},{"pmid":"35232969","id":"PMC_35232969","title":"Loss of MIG-6 results in endometrial progesterone resistance via ERBB2.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35232969","citation_count":35,"is_preprint":false},{"pmid":"31352322","id":"PMC_31352322","title":"Ac-YVAD-cmk improves neurological function by inhibiting caspase-1-mediated inflammatory response in the intracerebral hemorrhage of rats.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31352322","citation_count":35,"is_preprint":false},{"pmid":"32827461","id":"PMC_32827461","title":"Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity.","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32827461","citation_count":35,"is_preprint":false},{"pmid":"14745725","id":"PMC_14745725","title":"Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas.","date":"2004","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14745725","citation_count":34,"is_preprint":false},{"pmid":"15802529","id":"PMC_15802529","title":"CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15802529","citation_count":32,"is_preprint":false},{"pmid":"36472587","id":"PMC_36472587","title":"CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/36472587","citation_count":31,"is_preprint":false},{"pmid":"34865465","id":"PMC_34865465","title":"Highly Sensitive Immuno-CRISPR Assay for CXCL9 Detection.","date":"2021","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34865465","citation_count":29,"is_preprint":false},{"pmid":"31783271","id":"PMC_31783271","title":"CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis.","date":"2019","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31783271","citation_count":29,"is_preprint":false},{"pmid":"21349590","id":"PMC_21349590","title":"Equine herpesvirus type-1 modulates CCL2, CCL3, CCL5, CXCL9, and CXCL10 chemokine expression.","date":"2011","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/21349590","citation_count":29,"is_preprint":false},{"pmid":"21775092","id":"PMC_21775092","title":"CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis.","date":"2011","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/21775092","citation_count":29,"is_preprint":false},{"pmid":"32181005","id":"PMC_32181005","title":"Effective Treatments for Bladder Cancer Affecting CXCL9/CXCL10/CXCL11/CXCR3 Axis: A Review.","date":"2020","source":"Oman medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32181005","citation_count":28,"is_preprint":false},{"pmid":"17490641","id":"PMC_17490641","title":"VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins.","date":"2007","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17490641","citation_count":28,"is_preprint":false},{"pmid":"4373439","id":"PMC_4373439","title":"Salmonella typhimurium mutants defective in cytidine monophosphate kinase (cmk).","date":"1974","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/4373439","citation_count":27,"is_preprint":false},{"pmid":"25151370","id":"PMC_25151370","title":"The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.","date":"2014","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/25151370","citation_count":26,"is_preprint":false},{"pmid":"15851567","id":"PMC_15851567","title":"Synthesis of alpha-chemokines IP-10, I-TAC, and MIG are differentially regulated in human corneal keratocytes.","date":"2005","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/15851567","citation_count":26,"is_preprint":false},{"pmid":"36504808","id":"PMC_36504808","title":"CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36504808","citation_count":24,"is_preprint":false},{"pmid":"29673481","id":"PMC_29673481","title":"Cell-Autonomous Regulation of Dendrite Self-Avoidance by the Wnt Secretory Factor MIG-14/Wntless.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/29673481","citation_count":23,"is_preprint":false},{"pmid":"39447386","id":"PMC_39447386","title":"Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality.","date":"2024","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39447386","citation_count":22,"is_preprint":false},{"pmid":"12440735","id":"PMC_12440735","title":"Effects of polyphenolic anthrone derivatives, resistomycin and hypercin, on apoptosis in human megakaryoblastic leukemia CMK-7 cell line.","date":"2002","source":"Zeitschrift fur Naturforschung. C, Journal of biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/12440735","citation_count":22,"is_preprint":false},{"pmid":"36708947","id":"PMC_36708947","title":"CXCL9 Links Skin Inflammation and Fibrosis through CXCR3-Dependent Upregulation of Col1a1 in Fibroblasts.","date":"2023","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/36708947","citation_count":20,"is_preprint":false},{"pmid":"29228003","id":"PMC_29228003","title":"A MIG-15/JNK-1 MAP kinase cascade opposes RPM-1 signaling in synapse formation and learning.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29228003","citation_count":20,"is_preprint":false},{"pmid":"25398650","id":"PMC_25398650","title":"The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution.","date":"2014","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25398650","citation_count":20,"is_preprint":false},{"pmid":"23502337","id":"PMC_23502337","title":"Differential expression of CXCL1, CXCL9, CXCL10 and CXCL12 chemokines in alopecia areata.","date":"2013","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/23502337","citation_count":19,"is_preprint":false},{"pmid":"23209429","id":"PMC_23209429","title":"MIG-10 functions with ABI-1 to mediate the UNC-6 and SLT-1 axon guidance signaling pathways.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23209429","citation_count":19,"is_preprint":false},{"pmid":"21937599","id":"PMC_21937599","title":"MIG-15 and ERM-1 promote growth cone directional migration in parallel to UNC-116 and WVE-1.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21937599","citation_count":19,"is_preprint":false},{"pmid":"31285802","id":"PMC_31285802","title":"Urinary CXCL9 and CXCL10 Levels and Acute Renal Graft Rejection.","date":"2019","source":"International journal of organ transplantation medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31285802","citation_count":18,"is_preprint":false},{"pmid":"23241877","id":"PMC_23241877","title":"Cutaneous tumors cease CXCL9/Mig production as a result of IFN-γ-mediated immunoediting.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23241877","citation_count":17,"is_preprint":false},{"pmid":"17163262","id":"PMC_17163262","title":"Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study.","date":"2006","source":"Clinical drug investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17163262","citation_count":17,"is_preprint":false},{"pmid":"36355429","id":"PMC_36355429","title":"Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36355429","citation_count":16,"is_preprint":false},{"pmid":"15583799","id":"PMC_15583799","title":"Carcinoma cell-specific Mig-7: a new potential marker for circulating and migrating cancer cells.","date":"2005","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/15583799","citation_count":16,"is_preprint":false},{"pmid":"27462879","id":"PMC_27462879","title":"The CaM Kinase CMK-1 Mediates a Negative Feedback Mechanism Coupling the C. elegans Glutamate Receptor GLR-1 with Its Own Transcription.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27462879","citation_count":15,"is_preprint":false},{"pmid":"29593804","id":"PMC_29593804","title":"CXCL9 concentrations in cerebrospinal fluid and serum of patients with tick-borne encephalitis.","date":"2016","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/29593804","citation_count":15,"is_preprint":false},{"pmid":"33470761","id":"PMC_33470761","title":"Ac-FLTD-CMK inhibits pyroptosis and exerts neuroprotective effect in a mice model of traumatic brain injury.","date":"2021","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/33470761","citation_count":14,"is_preprint":false},{"pmid":"25702175","id":"PMC_25702175","title":"CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis.","date":"2015","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/25702175","citation_count":14,"is_preprint":false},{"pmid":"25976672","id":"PMC_25976672","title":"Mig-6 regulates endometrial genes involved in cell cycle and progesterone signaling.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25976672","citation_count":14,"is_preprint":false},{"pmid":"27671889","id":"PMC_27671889","title":"Antimicrobial activity and regulation of CXCL9 and CXCL10 in oral keratinocytes.","date":"2016","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27671889","citation_count":14,"is_preprint":false},{"pmid":"39078728","id":"PMC_39078728","title":"Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/39078728","citation_count":13,"is_preprint":false},{"pmid":"32552717","id":"PMC_32552717","title":"Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32552717","citation_count":13,"is_preprint":false},{"pmid":"36569039","id":"PMC_36569039","title":"CXCL9-11 chemokines and CXCR3 receptor in teleost fish species.","date":"2022","source":"Fish and shellfish immunology reports","url":"https://pubmed.ncbi.nlm.nih.gov/36569039","citation_count":12,"is_preprint":false},{"pmid":"36696410","id":"PMC_36696410","title":"Ac-YVAD-cmk ameliorated sevoflurane-induced cognitive dysfunction and revised mitophagy impairment.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36696410","citation_count":12,"is_preprint":false},{"pmid":"38342608","id":"PMC_38342608","title":"Pharmacological Polarization of Tumor-Associated Macrophages Toward a CXCL9 Antitumor Phenotype.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38342608","citation_count":12,"is_preprint":false},{"pmid":"38655660","id":"PMC_38655660","title":"Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.","date":"2024","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/38655660","citation_count":12,"is_preprint":false},{"pmid":"31696912","id":"PMC_31696912","title":"Rheumatoid arthritis and the Th1 chemokine MIG.","date":"2019","source":"La Clinica terapeutica","url":"https://pubmed.ncbi.nlm.nih.gov/31696912","citation_count":11,"is_preprint":false},{"pmid":"31550444","id":"PMC_31550444","title":"Inhibiting expression of Cxcl9 promotes angiogenesis in MSCs-HUVECs co-culture.","date":"2019","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/31550444","citation_count":11,"is_preprint":false},{"pmid":"33640906","id":"PMC_33640906","title":"Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.","date":"2021","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/33640906","citation_count":11,"is_preprint":false},{"pmid":"37644593","id":"PMC_37644593","title":"CT radiomics prediction of CXCL9 expression and survival in ovarian cancer.","date":"2023","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/37644593","citation_count":10,"is_preprint":false},{"pmid":"40238455","id":"PMC_40238455","title":"Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40238455","citation_count":10,"is_preprint":false},{"pmid":"29843645","id":"PMC_29843645","title":"MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29843645","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53202,"output_tokens":5913,"usd":0.12415},"stage2":{"model":"claude-opus-4-6","input_tokens":9505,"output_tokens":3221,"usd":0.192075},"total_usd":0.316225,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Recombinant human CXCL9 (Mig) induces transient elevation of intracellular Ca2+ and is chemotactic for tumor-infiltrating T lymphocytes and activated peripheral blood lymphocytes, but not neutrophils, monocytes, or B cells. Proteolytic cleavage at basic carboxy-terminal residues generates multiple secreted species of lower specific activity compared to full-length CXCL9.\",\n      \"method\": \"Calcium flux assay, modified Boyden chamber chemotaxis assay, SDS-PAGE of CHO-expressed recombinant protein, carboxy-terminal truncation analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple in vitro functional assays with recombinant protein and structure-activity analysis in single study\",\n      \"pmids\": [\"7595201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CXCL9 (Mig) and CXCL10 (IP-10) share the receptor CXCR3 on activated T cells, show reciprocal desensitization, and both inhibit neovascularization and hematopoietic progenitor cells while exerting antitumor effects.\",\n      \"method\": \"Reciprocal desensitization assays on activated T cells, in vitro and in vivo functional assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor sharing confirmed by reciprocal desensitization, replicated across multiple assays\",\n      \"pmids\": [\"9060447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CXCL9 and CXCL10 predominantly require the CXCR3 carboxyl-terminal domain and beta-arrestin1 for receptor internalization, whereas CXCL11 predominantly requires the third intracellular loop. Chemotaxis and calcium mobilization by all three ligands depend on the CXCR3 carboxyl terminus and the DRY sequence in the third transmembrane domain.\",\n      \"method\": \"CXCR3 domain deletion/mutation constructs, internalization assays, chemotaxis assays, calcium mobilization assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of receptor intracellular domains with multiple functional readouts\",\n      \"pmids\": [\"15150261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CXCL9 (Mig) contributes to the antitumor effects of IL-12 by inhibiting tumor vasculature; neutralizing antibodies to CXCL9 and CXCL10 substantially reduced the antitumor efficacy of local IL-12 treatment in athymic mice.\",\n      \"method\": \"In vivo neutralizing antibody treatment, tumor volume and survival measurement, gene/protein expression in tumor tissue\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo antibody neutralization with functional antitumor readout, single study\",\n      \"pmids\": [\"9738666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CXCL9 is required for CD4+ T lymphocyte recruitment and development of cardiac allograft vasculopathy; antibody neutralization of CXCL9 significantly reduced CD4+ T cell infiltration and intimal thickening. Macrophages (MOMA-2+) are the predominant source of CXCL9, and recipient CD4+ T cells are required for sustained CXCL9 production.\",\n      \"method\": \"In vivo antibody neutralization, histological assessment of intimal thickening, immunohistochemistry for CXCL9 source identification, MHC II-mismatched murine CAV model\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo neutralization with specific cellular phenotype readout, cell source identified by immunohistochemistry\",\n      \"pmids\": [\"12368204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL9 inhibits eosinophil chemoattraction and function via CCR3 and a Rac2-dependent mechanism: CXCL9 pretreatment blocks eotaxin-induced Rac GTPase activation and F-actin assembly, and this inhibitory activity is absent in CCR3-deficient and Rac2-deficient eosinophils.\",\n      \"method\": \"F-actin formation assay, chemotaxis assay, Rac GTPase activation assay, CCR3 and Rac2 gene-targeted cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — receptor and signaling molecule identified by genetic knockout plus functional assays\",\n      \"pmids\": [\"15802529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CXCL9 (MIG) exerts direct antibacterial activity against Streptococcus pyogenes; inhibition of CXCL9 expression reduces antibacterial activity at the surface of inflamed pharyngeal cells. S. pyogenes M1 secretes SIC (streptococcal inhibitor of complement) which inhibits the antibacterial activity of CXCL9.\",\n      \"method\": \"In vitro antibacterial assay, siRNA inhibition of CXCL9 expression in pharyngeal cells, tonsil fluid protein measurement\",\n      \"journal\": \"The Journal of infectious diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct antibacterial function demonstrated with knockdown and inhibitor, single study\",\n      \"pmids\": [\"17262710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Osteoblast-derived CXCL9 acts as an angiostatic factor by interacting with VEGF and preventing its binding to endothelial cells and osteoblasts, thereby inhibiting angiogenesis and osteogenesis. mTORC1 activates CXCL9 expression in osteoblasts by upregulating STAT1 transcription and increasing STAT1 binding to the CXCL9 promoter.\",\n      \"method\": \"In vitro binding assays (CXCL9-VEGF interaction), in vivo mouse bone models, ChIP assay (STAT1 binding to CXCL9 promoter), mTORC1 inhibition experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein-protein interaction, promoter ChIP, in vivo rescue experiments with multiple orthogonal methods\",\n      \"pmids\": [\"27966526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Macrophages are the predominant source of CXCL9 in tumors following dual PD-1/CTLA-4 immune checkpoint blockade; macrophage depletion abrogated CXCL9 production, CD8+ T cell infiltration, and therapeutic efficacy of ICB. CXCL9-mediated T cell recruitment is CXCR3-dependent.\",\n      \"method\": \"Macrophage depletion, neutralizing antibodies, NanoString analysis, flow cytometry, cytometric bead array, single-cell RNA-seq in patients\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — macrophage depletion plus CXCR3 blockade with functional T cell recruitment readout, confirmed in murine models and patient scRNA-seq\",\n      \"pmids\": [\"31636098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CXCL9, CXCL10, and CXCL11 gene expression is induced in SARS-CoV-2-infected Calu-3 lung epithelial cells via AKT-dependent signaling; treatment with the AKT inhibitor GSK690693 markedly reduced induction of these chemokines.\",\n      \"method\": \"Small molecule kinase inhibitor treatment (GSK690693), RT-qPCR, transgenic ACE2 mouse model infection\",\n      \"journal\": \"Viruses\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition identifies AKT pathway, confirmed in vivo, single study\",\n      \"pmids\": [\"34205098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCL9/10/11 signaling through CXCR3 upregulates PD-L1 expression in gastric cancer cells by activating the STAT3 and PI3K-Akt signaling pathways; blocking CXCR3 signaling diminished both PD-L1 upregulation and STAT3/Akt activation.\",\n      \"method\": \"Western blot for pSTAT3 and pAkt, CXCL9/10/11 stimulation and CXCR3 blockade, in vitro and in vivo experiments\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway activation confirmed by western blot with receptor blockade rescue, single study\",\n      \"pmids\": [\"29690901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCL9 promotes invasion of hepatocellular carcinoma cells by upregulating PREX2 (a Rac GTPase guanine nucleotide exchange factor) downstream of CXCR3/GPCR signaling; siRNA knockdown of PREX2 reduced CXCL9-enhanced invasion.\",\n      \"method\": \"Transwell invasion assay, recombinant CXCL9 treatment, PREX2 siRNA knockdown, RT-PCR\",\n      \"journal\": \"Journal of molecular histology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional invasion assay with siRNA knockdown identifying PREX2 as downstream effector, single study\",\n      \"pmids\": [\"25151370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCL9 inhibits proliferation of epithelial cells via activation of phospho-p70S6K, which promotes TGF-β secretion as a downstream mediator; p70S6K inhibition abolished this effect. CXCL9/CXCR3 interaction exacerbates chemotherapy-induced intestinal damage.\",\n      \"method\": \"Cell proliferation assay (MCF10A), ELISA for TGF-β, p70S6K inhibitor treatment, in vivo 5-FU mucositis mouse model, anti-CXCL9 antibody treatment\",\n      \"journal\": \"Journal of cancer research and clinical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway (p70S6K→TGF-β) identified with inhibitor and in vivo antibody rescue, single study\",\n      \"pmids\": [\"25398650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL9, but not CXCL10, inhibits collagen deposition in human pulmonary arterial smooth muscle cells via CXCR3, acting downstream of NKT cell-activated STAT1 signaling. This NKT-STAT1-CXCL9-CXCR3 axis opposes vascular fibrosis in pulmonary hypertension.\",\n      \"method\": \"CXCL9/CXCL10 treatment of hPASMCs, collagen deposition assay, CXCR3 blocking, NKT cell coculture, in vivo NKT cell activation (KRN7000), secretome analysis\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific (CXCR3) antifibrotic effect confirmed in vitro and in vivo, pathway defined by multiple orthogonal approaches\",\n      \"pmids\": [\"35763380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL9 drives skin fibrosis through CXCR3-dependent upregulation of Col1a1 in fibroblasts; Cxcl9-deficient and Cxcr3-deficient mice were protected from bleomycin-induced dermal fibrosis. Recombinant CXCL9, but not CXCL10, directly induced Col1a1 mRNA in cultured mouse fibroblasts.\",\n      \"method\": \"Cxcl9-/-, Cxcl10-/-, Cxcr3-/- knockout mouse bleomycin fibrosis model, recombinant CXCL9/CXCL10 treatment of fibroblasts, REX3 reporter mice for cell source tracking, RT-PCR for Col1a1\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic knockout of chemokine and receptor plus direct recombinant protein stimulation with gene expression readout\",\n      \"pmids\": [\"36708947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL9 overexpression in murine ovarian cancer models results in T cell accumulation and improved survival in an adaptive immune-dependent manner, and is sufficient to enable successful anti-PD-L1 therapy in otherwise ICB-resistant tumors.\",\n      \"method\": \"CXCL9 overexpression in ID8-Trp53-/- and ID8-Trp53-/-Brca2-/- mouse models, T cell depletion, anti-PD-L1 treatment, survival analysis\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo overexpression with adaptive immunity dependence confirmed by T cell depletion, single study\",\n      \"pmids\": [\"35314795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL9 stimulates proliferation and migration of cardiac fibroblasts; serum CXCL9 is elevated after myocardial infarction and in isoproterenol-treated rats with cardiac fibrosis.\",\n      \"method\": \"In vitro cardiac fibroblast proliferation and migration assays with CXCL9 treatment, ELISA in patient sera and rat model\",\n      \"journal\": \"Journal of clinical medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single in vitro functional assay, no mechanistic pathway identified\",\n      \"pmids\": [\"31083544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Glucocorticoids act directly on renal tubular epithelial cells (not on T cells) to abolish CXCL9 and CXCL10 expression, thereby preventing CXCR3+CD4+ T cell recruitment to inflamed kidneys and protecting from immune-mediated glomerulonephritis.\",\n      \"method\": \"In vivo crescentic glomerulonephritis model with steroid treatment, in vitro steroid treatment of tubular epithelial cells and T cells, single-cell and morphological analyses of kidney biopsies\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-specific mechanism confirmed by in vitro dissection plus in vivo model, single study\",\n      \"pmids\": [\"36355429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DPP-4 cleaves the two N-terminal amino acids of CXCL9, converting it from a CXCR3 agonist to a competitive antagonist that can still bind CXCR3 but no longer activates it. Addition of an N-terminal glutamine renders CXCL9-Fc resistant to DPP-4 cleavage while retaining full CXCR3 agonist activity.\",\n      \"method\": \"Biochemical DPP-4 cleavage assays, computational modeling, CXCR3 activation assays, N-terminal glutamine mutant engineering\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical assay with structure-activity mutagenesis defining DPP-4 as a post-translational modifier that converts CXCL9 into a CXCR3 antagonist\",\n      \"pmids\": [\"40238455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL9-expressing proinflammatory macrophages (F480+MHCII+Ly6Clo) are the primary source of CXCL9 in tumors; the efficacy of anti-PD-L1 (avelumab) is dependent on both Cxcr3 and Cxcl9, as demonstrated in mouse tumor models.\",\n      \"method\": \"scRNA-seq, flow cytometry, Cxcr3 and Cxcl9 functional dependence in murine tumor models, pre-treatment biopsy analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CXCL9/CXCR3 functional requirement confirmed in vivo, macrophage source confirmed by scRNA-seq and flow cytometry\",\n      \"pmids\": [\"32640238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CXCL9 (Mig) directly induces proliferation of human mesangial cells in vitro through functional CXCR3 expressed on these cells, in addition to its role as a chemoattractant.\",\n      \"method\": \"Flow cytometry for CXCR3 on mesangial cells, intracellular Ca2+ influx assay, mesangial cell proliferation assay with CXCL9/IP-10 treatment\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor expression confirmed plus direct functional proliferation assay, single study\",\n      \"pmids\": [\"10589690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In murine CXCL9/10-engineered dendritic cell vaccination, antitumor efficacy is dependent on CD4+ and CD8+ T cells and CXCR3-dependent T cell trafficking from the lymph node, establishing the mechanistic requirement for the CXCL9-CXCR3 axis in DC-mediated immune activation.\",\n      \"method\": \"CD4/CD8 T cell depletion, CXCR3 blockade, intratumoral dendritic cell vaccination in murine NSCLC models, flow cytometry\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CXCR3-dependent trafficking mechanistically confirmed by blockade in vivo, single study\",\n      \"pmids\": [\"38518770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In cervical cancer, HPV proteins E6 and E7 induce LIF expression via the NFκB pathway, and LIF represses CXCL9 expression in tumor-associated macrophages; LIF blockade restores CXCL9 production and promotes CD8+ T cell tumor infiltration.\",\n      \"method\": \"Primary pDC and macrophage cultures, LIF blockade, syngeneic animal models, patient-derived tumor models, IFN-γ pathway analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — upstream repressor (LIF via NFκB) and downstream consequence (CXCL9, CD8+ T infiltration) defined by intervention studies, single study\",\n      \"pmids\": [\"39078728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL9 secreted by osteoblast-derived MSCs in osteogenic conditions acts via mTOR/STAT1 signaling to counter-regulate VEGF and suppress angiogenesis in MSC-endothelial co-culture; rapamycin inhibition of mTOR reduced CXCL9 and restored angiogenic capacity.\",\n      \"method\": \"MSC-HUVEC co-culture, rapamycin treatment, VEGF binding competition assay, osteogenic differentiation assay\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mTOR/STAT1 pathway confirmed by pharmacological inhibition with functional angiogenesis readout, single study\",\n      \"pmids\": [\"31550444\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL9 (MIG) is an IFN-γ-inducible CXC chemokine that signals primarily through CXCR3 on activated T and NK cells to drive chemotaxis and calcium flux; it is subject to DPP-4-mediated N-terminal cleavage that converts it into a CXCR3 competitive antagonist, and it exerts angiostatic effects by directly binding and sequestering VEGF. It inhibits eosinophil responses via CCR3/Rac2-dependent disruption of actin cytoskeletal signaling, can drive fibroblast collagen synthesis (Col1a1) and skin fibrosis via CXCR3, and is produced predominantly by macrophages (under mTORC1/STAT1 control) to recruit CXCR3+ cytotoxic T cells in tumor and inflammatory contexts.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CXCL9 (MIG) is an interferon-γ-inducible CXC chemokine that orchestrates immune cell trafficking, angiostasis, and tissue remodeling through CXCR3-dependent and CXCR3-independent mechanisms. It signals through CXCR3 on activated T cells and NK cells to elicit calcium flux and chemotaxis — requiring the receptor's carboxyl-terminal domain, DRY motif, and β-arrestin1 for internalization — and is the principal macrophage-derived chemokine that recruits CXCR3⁺ CD8⁺ T cells into tumors, a function essential for the efficacy of immune checkpoint blockade [PMID:7595201, PMID:15150261, PMID:32640238, PMID:31636098]. DPP-4 cleaves the two N-terminal residues of CXCL9 converting it from a CXCR3 agonist into a competitive antagonist, while CXCL9 also exerts angiostatic activity by directly binding and sequestering VEGF downstream of mTORC1/STAT1-driven transcription [PMID:40238455, PMID:27966526]. Beyond immune recruitment, CXCL9 inhibits eosinophil function through CCR3/Rac2-dependent disruption of actin polymerization, directly induces Col1a1 in fibroblasts to promote dermal fibrosis via CXCR3, and opposes vascular smooth-muscle collagen deposition in pulmonary hypertension, illustrating context-dependent pro- and anti-fibrotic roles [PMID:15802529, PMID:36708947, PMID:35763380].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that CXCL9 is a T-cell-selective chemoattractant resolved the cellular target specificity of this IFN-γ-inducible chemokine and showed that its C-terminal basic tail modulates bioactivity.\",\n      \"evidence\": \"Recombinant CXCL9 calcium flux and Boyden chamber chemotaxis on TILs and PBLs; C-terminal truncation analysis\",\n      \"pmids\": [\"7595201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity unknown at this stage\", \"In vivo relevance of C-terminal processing not tested\", \"Mechanism of T-cell selectivity undefined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying CXCR3 as the shared receptor for CXCL9, CXCL10, and CXCL11 unified these IFN-γ-inducible chemokines into a single signaling axis and linked them to antiangiogenic and antitumor activity.\",\n      \"evidence\": \"Reciprocal desensitization assays on activated T cells; neovascularization and hematopoietic progenitor inhibition assays\",\n      \"pmids\": [\"9060447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand-specific signaling bias through CXCR3 not resolved\", \"Structural basis of receptor recognition unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that neutralizing CXCL9 reduced IL-12-mediated tumor regression in vivo established its non-redundant role as an angiostatic effector in antitumor immunity.\",\n      \"evidence\": \"In vivo anti-CXCL9 neutralizing antibody in athymic mouse tumor models\",\n      \"pmids\": [\"9738666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cannot distinguish T-cell-independent angiostatic from immune-mediated antitumor effects in this system\", \"Contribution of CXCL10 not fully separated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showing that macrophages are the predominant CXCL9 source and that CXCL9 neutralization blocks CD4⁺ T cell recruitment defined the macrophage–CXCL9–T cell axis in transplant vasculopathy.\",\n      \"evidence\": \"Anti-CXCL9 antibody in MHC II-mismatched murine cardiac allograft model; MOMA-2 immunohistochemistry for cell source\",\n      \"pmids\": [\"12368204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CXCL10/11 not fully controlled\", \"Downstream intracellular signaling in recruited T cells not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapping the CXCR3 domains required for CXCL9-driven internalization, chemotaxis, and calcium mobilization revealed that CXCL9 signals preferentially through the receptor's C-terminal tail and β-arrestin1, distinct from CXCL11.\",\n      \"evidence\": \"CXCR3 deletion/point mutant constructs with internalization, chemotaxis, and calcium flux readouts\",\n      \"pmids\": [\"15150261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biased signaling consequences (G-protein vs. β-arrestin) not measured for downstream gene expression\", \"No structural data for ligand–receptor interface\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovering that CXCL9 inhibits eosinophil responses through CCR3 and Rac2 revealed a CXCR3-independent anti-inflammatory mechanism acting on allergic effector cells.\",\n      \"evidence\": \"CCR3⁻/⁻ and Rac2⁻/⁻ eosinophils; F-actin, Rac-GTP, and chemotaxis assays\",\n      \"pmids\": [\"15802529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding mode of CXCL9 to CCR3 not structurally defined\", \"In vivo relevance in allergic disease not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Finding that CXCL9 has direct antimicrobial activity against Streptococcus pyogenes expanded its function beyond chemotaxis to innate host defense, while identifying SIC as a bacterial counter-strategy.\",\n      \"evidence\": \"In vitro bactericidal assay; siRNA knockdown in pharyngeal epithelial cells\",\n      \"pmids\": [\"17262710\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antimicrobial mechanism (membrane disruption vs. other) not defined\", \"In vivo contribution to pharyngeal defense not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that CXCL9 directly binds VEGF to block its receptor engagement, and that mTORC1/STAT1 drives CXCL9 transcription, defined a transcriptional–angiostatic circuit operating in osteoblasts.\",\n      \"evidence\": \"CXCL9–VEGF binding assay, STAT1 ChIP on CXCL9 promoter, mTORC1 inhibition, in vivo bone models\",\n      \"pmids\": [\"27966526\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and affinity of CXCL9–VEGF interaction not quantified biophysically\", \"Relative contribution of CXCR3-mediated vs. VEGF-sequestration-mediated angiostasis not separated in vivo\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multiple groups converged on tumor-associated macrophages as the critical CXCL9 source required for CXCR3-dependent CD8⁺ T cell infiltration and anti-PD-1/PD-L1 efficacy, establishing CXCL9 as a gatekeeper of checkpoint immunotherapy response.\",\n      \"evidence\": \"Macrophage depletion, CXCR3/CXCL9 genetic or antibody blockade in murine tumor models; patient scRNA-seq validation\",\n      \"pmids\": [\"31636098\", \"32640238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals that sustain macrophage CXCL9 production in the tumor microenvironment beyond IFN-γ not fully mapped\", \"Whether CXCL9 vs. CXCL10 have non-redundant roles in human ICB response not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identifying opposing fibrotic roles — CXCL9 inhibits collagen deposition in pulmonary vascular smooth muscle yet promotes dermal fibrosis via fibroblast Col1a1 induction — revealed that CXCR3-mediated fibrotic outcomes are tissue- and cell-type-specific.\",\n      \"evidence\": \"hPASMC collagen assay with CXCR3 blockade (pulmonary); Cxcl9⁻/⁻ and Cxcr3⁻/⁻ mice in bleomycin skin fibrosis model with direct fibroblast stimulation (dermal)\",\n      \"pmids\": [\"35763380\", \"36708947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcription factors linking CXCR3 to Col1a1 induction in fibroblasts not identified\", \"Whether DPP-4 cleavage modulates fibrotic vs. antifibrotic activity not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defining DPP-4 as a post-translational switch that converts full-length CXCL9 from a CXCR3 agonist to a competitive antagonist explained how proteolytic processing negatively regulates the CXCL9–CXCR3 axis and opened a strategy for engineering cleavage-resistant variants.\",\n      \"evidence\": \"Biochemical DPP-4 cleavage assay, CXCR3 activation assay, N-terminal glutamine mutant engineering\",\n      \"pmids\": [\"40238455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo impact of DPP-4-processed CXCL9 on T cell recruitment and tumor immunity not demonstrated\", \"Whether DPP-4-cleaved CXCL9 retains VEGF-binding or antimicrobial activities unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CXCL9–CXCR3 vs. CXCL9–CCR3 binding selectivity, the intracellular signaling cascade linking CXCR3 to opposing fibrotic outcomes in different cell types, and whether DPP-4-mediated antagonist conversion operates in vivo to shape tumor immune evasion.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal/cryo-EM structure of CXCL9 bound to CXCR3 or CCR3\", \"Signaling divergence downstream of CXCR3 in fibroblasts vs. smooth muscle cells undefined\", \"In vivo functional relevance of DPP-4-cleaved CXCL9 antagonism not tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 18]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [7, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 4, 7, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 8, 19, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 10, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CXCR3\", \"CCR3\", \"VEGF\", \"DPP4\", \"STAT1\", \"PREX2\"],\n    \"other_free_text\": []\n  }\n}\n```"}